CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alvotech SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alvotech SA
9, Rue De Bitbourg
LUXEMBOURG, 1273  Luxembourg Ticker: ALVOALVO
Business Summary
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Chief Executive Officer, Founder RobertWessman 54 1/1/2023 1/1/2019
Independent Deputy Chairman of the Board Richard J.Davies 62
Chief Financial Officer JoelMorales 45 2/1/2020 2/1/2020
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Alvotech Hannover GmbH Feodor Lynen Str. 35 Hannover Germany
Alvotech Germany GmbH Karl-Heinz-Beckurts-Str. 13 Julich Germany
Alvotech hf Smaratorgi 3, 201 Kopavogi Iceland
Alvotech Swiss AG Thurgauerstrasse 54 Zurich Switzerland
Alvotech USA Inc. 1201 Wilson Blvd. Arlington VA United States

Business Names
Business Name
ALVO
Alvotech Germany GmbH
Alvotech Hannover GmbH
7 additional Business Names available in full report.

General Information
Number of Employees: 999 (As of 12/31/2023)
Outstanding Shares: 266,821,844 (As of 2/15/2024)
Shareholders: 8
Stock Exchange: NASD
Federal Tax Id: 981551592


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024